Kintara Therapeutics (STU:3DMA) Beginning Cash Position : €0.61 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics Beginning Cash Position?

Kintara Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2024 was €0.61 Mil.

Kintara Therapeutics's quarterly Beginning Cash Position declined from Sep. 2023 (€1.44 Mil) to Dec. 2023 (€0.20 Mil) but then increased from Dec. 2023 (€0.20 Mil) to Mar. 2024 (€0.61 Mil).

Kintara Therapeutics's annual Beginning Cash Position increased from Jun. 2021 (€1.99 Mil) to Jun. 2022 (€9.97 Mil) and increased from Jun. 2022 (€9.97 Mil) to Jun. 2023 (€10.87 Mil).

Kintara Therapeutics Beginning Cash Position Historical Data

The historical data trend for Kintara Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Beginning Cash Position Chart

Kintara Therapeutics Annual Data

Trend

Dec13

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Beginning Cash Position

Get a 7-Day Free Trial

5.29

3.30

1.99

9.97

10.87

Kintara Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															4.55	2.81	1.44	0.20	0.61

Kintara Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Kintara Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintara Therapeutics (STU:3DMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (STU:3DMA) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

KTRA:USA

Address

9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121

Website

https://www.kintara.com

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics (STU:3DMA) Headlines

No Headlines